Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNYR vs AHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

SNYR Overall Winner 6-Pillar Tally: SNYR 3 – 2 AHG (1 Tie) Matrix Metrics: SNYR 5 – 5 AHG

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over Akso Health Group ADS (AHG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas AHG carries 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin).

  • Growth vs. Quality Trade-Off: SNYR earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. AHG 38.2/100 SELL) and -0.86β · 868% Vol risk profile, whereas AHG leads top-line expansion (-12.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNYR vs AHG
SNYR NASDAQ Head-to-Head Winner
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14
AHG NASDAQ
Akso Health Group ADS
Services-Business Services, Nec
$1.26
-1.56% 1D
Market Cap $1.1B
TTM Revenue $14M
Forward P/E N/M
Beta / 30D Vol 0.38β · 101% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 20.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.6 · SMA20: $1.30 · SMA50: $1.14

6-Pillar Scorecard Institutional Category Breakdown (SNYR 3 – 2 AHG)

Columns: Metric · SNYR · AHG
1. Valuation Multiples SNYR
Forward P/E 0.6x N/M
Trailing P/E 0.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x 79.3x
2. Growth & Scale AHG
Revenue Growth (YoY) -32.8% -12.9%
Earnings Growth (YoY) -90.6% +0.0%
TTM Revenue (USD) $28M $14M
Market Cap $4.1M $1.1B
3. Profitability & Quality SNYR
Gross Margin 65.4% -0.1%
Operating Margin -10.3% -28.9%
Net Profit Margin -57.0% -135.0%
Return on Equity (ROE) -361.1% -9.8%
4. Balance Sheet & Cash Flow AHG
Cash Generation (TTM) -$3.8M -$1.6M EBITDA
Cash Flow Margin -13.7% -11.8% EBITDA Mgn
Net Cash / Leverage -361.1% ROE $0.21 Book/Sh · -9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 75.7% of Rev ($21M) 28.8% of Rev ($4.0M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNYR (5) vs AHG (5)
Institutional Metric SNYR AHG Criterion Row Edge
Market Capitalization
Scale
$4.1M $1.1B Larger Scale AHG
Trailing P/E Ratio
Valuation
0.6x N/M Lower Multiple SNYR
Forward P/E Ratio
Valuation
0.6x N/M Lower Multiple SNYR
Revenue Growth (YoY)
Growth
-32.8% -12.9% Higher Growth AHG
Operating Margin (TTM)
Profitability
-10.3% -28.9% Higher Margin SNYR
Net Profit Margin
Profitability
-57.0% -135.0% Higher Margin SNYR
Return on Equity (ROE)
Capital Efficiency
-361.1% -9.8% Higher ROE AHG
52-Week Range Position
Momentum
1% ($0–$3) 32% ($1–$2) Stronger Trend AHG
Beta / 30D Volatility
Risk Regime
-0.86β · 868% Vol 0.38β · 101% Vol Lower Realized Risk AHG
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 38.2 / 100 (SELL) Higher Composite SNYR
Trailing 12M Revenue (USD)
Operating Scale
$28M $14M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.4% -0.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 79.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.8M (-361.1% ROE) -$1.6M EBITDA ($0.21 Book/Sh · -9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNYR +11.95 pp
SNYR: -16.28% · AHG: -28.23%
3M Horizon AHG +15.35 pp
SNYR: -53.37% · AHG: -38.02%
6M Horizon AHG +25.61 pp
SNYR: -93.14% · AHG: -67.53%
1Y Horizon AHG +46.46 pp
SNYR: -95.44% · AHG: -48.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNYR vs AHG. Trailing 12-month operating profitability (SNYR -10.3% vs AHG -28.9%) and valuation multiples (SNYR 0.6x vs AHG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SNYR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin65.4%
Op. Margin-10.3%
ROE / Fwd P/E-361.1% · 0.6x
AHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14M
Gross Margin-0.1%
Op. Margin-28.9%
ROE / Fwd P/E-9.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published
AHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $1.1B market capitalization and -28.9% operating margin.
OpEx & R&D Reinvestment 28.8% of Rev ($4.0M)
90D Engineering Disclosures 0 Published

Investor FAQ SNYR vs AHG Key Questions & Quantitative Answers

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over Akso Health Group ADS (AHG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas AHG carries 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin). Growth vs. Quality Trade-Off: SNYR earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. AHG 38.2/100 SELL) and -0.86β · 868% Vol risk profile, whereas AHG leads top-line expansion (-12.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

AHG leads the Growth & Scale pillar: SNYR posts -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin), compared with AHG at -12.9% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (-0.1% gross margin, -28.9% operating margin). On trailing 12-month operating scale, SNYR generates $28M in USD-normalized revenue versus $14M for AHG. In operating R&D and SG&A reinvestment, SNYR deploys 75.7% of Rev ($21M) (0 90-day corporate R&D disclosures) versus 28.8% of Rev ($4.0M) (0 disclosures) for AHG.

SNYR screens cheaper on headline valuation multiples. SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin), whereas AHG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 79.3x EV/Revenue (-11.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNYR (-361.1% ROE) versus AHG (-9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk). By comparison, AHG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.38β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.